Stemline Therapeutics, Inc. Announces Exercise of Over-Allotment Option

Stemline Therapeutics, Inc. Announces Exercise of Over-Allotment Option

[at noodls] – NEW YORK, Jan. 29, 2013 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) … more

View todays social media effects on STML

View the latest stocks trending across Twitter. Click to view dashboard

See who Stemline is hiring next, click here to view

Share this post